Navigation Links
Webcast Alert: Isis Pharmaceuticals' 2012 Financial Results and Highlights Conference Call
Date:2/21/2013

CARLSBAD, Calif., Feb. 21, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:What: 

Isis Pharmaceuticals' 2012 Financial Results and Highlights Conference CallWhen:

Thursday, February 28, 2013 at 12:00 p.m. ET / 9:00 a.m. PTWhere:

www.isispharm.comHow:

Live on the Internet.  Simply log onto our Web site listed above. If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets, including Europe.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENTThis press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Thoratec Schedules First Quarter Conference Call, Webcast
2. Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
3. Henry Schein to Webcast First Quarter 2012 Conference Call Tuesday, May 8, at 10:00 a.m. EDT
4. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
6. Pro-Dex, Inc. Announces Fiscal 2012 Third Quarter Financial Results Conference Call and Webcast
7. Cempra, Inc. to Report First Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on May 10, 2012
8. Heartware Schedules First Quarter Conference Call And Webcast
9. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
10. HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
11. Ampio Pharmaceuticals Schedules 2012 Update Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 2017  Semler Scientific, Inc. (OTCQB: SMLR), an ... improve the clinical effectiveness and efficiency of healthcare ... quarter ended March 31, 2017. ... to identify when preventive care options are appropriate, ... heart attacks or strokes occur," said Doug ...
(Date:5/6/2017)... SKANEATELES FALLS, N.Y. , May 5, 2017 /PRNewswire/ ... expansion that will add approximately 100,000 square feet to ... announced in September 2016 its commitment to bring more ... York , where Welch Allyn has maintained a ... facility will help accommodate these new positions, a large ...
(Date:5/4/2017)... Israel , May 4, 2017  DarioHealth Corp. ... mobile health and big data solutions, today announced that ... A&D Company, and STI Technologies Limited to lower diabetes ... immediately. Through STI,s innoviCares card, which is available throughout ... , DarioHealth customers will be eligible for additional savings ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... , ... Technique, technique, technique – with a dash of common sense. Those ... and exercise or simply lifting heavy objects, advises Dr. Kaliq Chang, interventional pain management ... says. “Improper technique in lifting anything heavy or an attempt to lift too much ...
(Date:5/23/2017)... City (PRWEB) , ... May 23, 2017 , ... ... Population Health and Clinical Integration company, announced today that its iClinic V12.2 ... Home (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards which emphasize ...
(Date:5/23/2017)... ... 2017 , ... Allegheny Health Network and the Alexis Joy ... Women’s Behavioral Health at West Penn Hospital , a unique facility that will ... pregnancy-related depression. Construction of the Center is underway with a scheduled opening in ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, ... steady since 2009, according to a Workers Compensation Research Institute (WCRI) study, a ... the North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and ...
(Date:5/23/2017)... ... May 23, 2017 , ... i2i Population Health, a ... KLAS category winner, has named Daniel P. Bullington as chief technology officer. , ... platform and product offerings,” says Justin Neece, president. “Daniel is an excellent fit ...
Breaking Medicine News(10 mins):